John Chen Hsiang1, Grace Lai-Hung Wong2, Yee-Kit Tse3, Vincent Wai-Sun Wong2, Terry Cheuk-Fung Yip4, Henry Lik-Yuen Chan5. 1. Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China. 2. Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China. 3. Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. 4. Department of Statistics, The Chinese University of Hong Kong, Hong Kong, China. 5. Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China. Electronic address: hlychan@cuhk.edu.hk.
Abstract
BACKGROUND & AIMS: The use of statin in hepatocellular carcinoma (HCC) and death prevention is still uncertain among hepatitis B infected (HBV) patients. This study aimed to examine the effect of statin on HCC and death in a HBV population. METHODS: We conducted a hospital-based population study of HBV patients, using the Hospital Authority database in Hong Kong. We defined statin use by landmark analysis to abrogate "immortal time bias" and propensity score (PS) weighting to minimize baseline confounders and "indication bias". Multiple imputations for missing data were performed. The weighted Cox regression analyses was performed for the risk of HCC (adjusting for competing mortality) and death. RESULTS: A total of 73,499 patients with a crude HCC incidence of 1.75 per 100 patient-years were entered into the 2-year landmark analysis. After landmark analysis and PS weighting of baseline covariates, statin users had a 32% risk reduction in HCC (weighted sub-hazard ratio (SHR) 0.68; 95% CI 0.48-0.97) compared to non-users. There was no decreased risk of death in statin users (weighted HR 0.92; 0.76-1.11, p=0.386). In subgroup analysis, concurrent statin and nucleos(t)ide analogue (NA) use was associated with 59% risk reduction in HCC (weighted SHR 0.41; 0.19-0.89, p=0.023) compared to NA use alone. CONCLUSION: In this HBV cohort adjusted for confounders and biases, statin use is associated with reduced HCC risk by 32%. Additive HCC chemopreventive effect was seen with the concomitant use of NA and statin. Further prospective studies are warranted to investigate the potential use of statin in NA users.
BACKGROUND & AIMS: The use of statin in hepatocellular carcinoma (HCC) and death prevention is still uncertain among hepatitis B infected (HBV) patients. This study aimed to examine the effect of statin on HCC and death in a HBV population. METHODS: We conducted a hospital-based population study of HBV patients, using the Hospital Authority database in Hong Kong. We defined statin use by landmark analysis to abrogate "immortal time bias" and propensity score (PS) weighting to minimize baseline confounders and "indication bias". Multiple imputations for missing data were performed. The weighted Cox regression analyses was performed for the risk of HCC (adjusting for competing mortality) and death. RESULTS: A total of 73,499 patients with a crude HCC incidence of 1.75 per 100 patient-years were entered into the 2-year landmark analysis. After landmark analysis and PS weighting of baseline covariates, statin users had a 32% risk reduction in HCC (weighted sub-hazard ratio (SHR) 0.68; 95% CI 0.48-0.97) compared to non-users. There was no decreased risk of death in statin users (weighted HR 0.92; 0.76-1.11, p=0.386). In subgroup analysis, concurrent statin and nucleos(t)ide analogue (NA) use was associated with 59% risk reduction in HCC (weighted SHR 0.41; 0.19-0.89, p=0.023) compared to NA use alone. CONCLUSION: In this HBV cohort adjusted for confounders and biases, statin use is associated with reduced HCC risk by 32%. Additive HCC chemopreventive effect was seen with the concomitant use of NA and statin. Further prospective studies are warranted to investigate the potential use of statin in NA users.
Authors: Sehrish Kamal; Muhammad Ali Khan; Ankur Seth; George Cholankeril; Deepansh Gupta; Utkarsh Singh; Faisal Kamal; Colin W Howden; Christopher Stave; Satheesh Nair; Sanjaya K Satapathy; Aijaz Ahmed Journal: Am J Gastroenterol Date: 2017-06-06 Impact factor: 10.864
Authors: Wenshu Tang; Jingying Zhou; Weiqin Yang; Yu Feng; Haoran Wu; Myth T S Mok; Lingyun Zhang; Zhixian Liang; Xiaoyu Liu; Zhewen Xiong; Xuezhen Zeng; Jing Wang; Jiahuan Lu; Jingqing Li; Hanyong Sun; Xiaoyu Tian; Philip Chun Yeung; Yong Hou; Heung Man Lee; Candice C H Lam; Howard H W Leung; Anthony W H Chan; Ka Fai To; John Wong; Paul B S Lai; Kelvin K C Ng; Simon K H Wong; Vincent W S Wong; Alice P S Kong; Joseph J Y Sung; Alfred S L Cheng Journal: Cell Mol Immunol Date: 2022-05-20 Impact factor: 22.096
Authors: Martin Janicko; Sylvia Drazilova; Daniel Pella; Jan Fedacko; Peter Jarcuska Journal: World J Gastroenterol Date: 2016-07-21 Impact factor: 5.742